Latest News
MaxCyte, Inc.
- MaxCyte(MXCT) Stock Options Chain | Quotes & News
- Liontrust Investment Partners LLP Buys MaxCyte Inc (MXCT) -- Shares Look 44% Undervalued on GF Value
- Liontrust Investment Partners Discloses Investment at MaxCyte with 5.03% Stake
- An investor reports over 5% of MaxCyte (MXCT) after October 14 share purchases.
- MaxCyte, Inc. Provides Preliminary Unaudited Revenue Guidance for the Third Quarter Ended September 30, 2026 and Updates Revenue Guidance for the Second Half of the Year 2026
- MaxCyte, Inc. Revises Revenue Guidance for the Full Year 2026
- MaxCyte raises 2026 revenue guidance on strong Q3 results
- MaxCyte reports Q3 preliminary revenue $9.1M and raises 2026 revenue guidance to ~$34M
- MaxCyte raises 2026 revenue guidance after strong Q3 results
- MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
- MaxCyte stock surges 25% on raised 2026 revenue guidance
- People on the Move: Sidharth Kapileshwar Named Chief Corporate Development Officer of MaxCyte
Headlines from the last 30 days, linking to the original publishers. See all market news →